CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 45 enrolled
Drug / intervention
Lenalidomidedrug
Likely dose
Lenalidomide 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00267059
NCT00267059Phase 2Completed
CompareCT.gov

Lenalidomide (Revlimid) in Patients With Previously Treated Chronic Lymphocytic Leukemia

M.D. Anderson Cancer Center·interventional·Posted Dec 20, 2005·Updated Aug 7, 2012

In Brief

A Phase 2 clinical trial evaluating Lenalidomide for Chronic Lymphocytic Leukemia and Leukemia. Completed, enrolled 45 participants across 1 site.

Detailed Summary

The goal of this clinical research study is to learn if lenalidomide (Revlimid®) can help to control CLL in patients who have already received standard therapy. The safety of lenalidomide will also be studied.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Lymphocytic Leukemia, Leukemia
CountriesUnited States
CollaboratorsCelgene Corporation

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 20, 2005
Enrollment StartDec 1, 2005
Primary CompletionAug 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 20.5 years ago

Interventions

Lenalidomidedrug

10 mg/day, orally once a day for 28 days